![Isabelle Dufresne](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Isabelle Dufresne
Keine laufenden Positionen mehr
Profil
Isabelle Dufresne served as Director-Investments at Gestion Bio Innovation, Inc. and Director at Chlorion Pharma, Inc. She also served as Director at Allostera Pharma, Inc. from 2009 to 2013 and as Vice-President at Gestion Fonds InnovExport Commandité inc from 2019 to 2022.
Dufresne earned an undergraduate degree from the University of Quebec and graduate and MBA degrees from Université Laval.
Ehemalige bekannte Positionen von Isabelle Dufresne
Unternehmen | Position | Ende |
---|---|---|
Gestion Fonds InnovExport Commandité inc
![]() Gestion Fonds InnovExport Commandité inc Investment ManagersFinance Gestion Fonds InnovExport Commandité inc (Fonds Innovexport) is a venture capital firm founded in 2016. The firm is headquartered in Quebec, Canada. | Private Equity Investor | 01.03.2022 |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Direktor/Vorstandsmitglied | 09.09.2013 |
Chlorion Pharma, Inc.
![]() Chlorion Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Chlorion Pharma, Inc. Develops small molecule leads for the treatment of naturopathic pain and epilepsy. It develops therapeutics for the treatment of neuropathic pain and epilepsy. The company was founded by Jeffrey A. M. Coull, Yves De Koninck and Martin Gagnon in 2004 and is headquartered in Laval, Canada. | Direktor/Vorstandsmitglied | - |
Gestion Bio Innovation, Inc.
![]() Gestion Bio Innovation, Inc. Investment ManagersFinance Gestion Bio Innovation Inc (Gestion Bio Innovation) is a venture capital subsidiary of Centre Québécois de Valorisation des Biotechnologies founded in 1900. The firm is headquartered in Quebec, Canada. | Direktor der Forschung - Eigenkapital | - |
Ausbildung von Isabelle Dufresne
Université Laval | Graduate Degree |
University of Quebec | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Gestion Bio Innovation, Inc.
![]() Gestion Bio Innovation, Inc. Investment ManagersFinance Gestion Bio Innovation Inc (Gestion Bio Innovation) is a venture capital subsidiary of Centre Québécois de Valorisation des Biotechnologies founded in 1900. The firm is headquartered in Quebec, Canada. | Finance |
Chlorion Pharma, Inc.
![]() Chlorion Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Chlorion Pharma, Inc. Develops small molecule leads for the treatment of naturopathic pain and epilepsy. It develops therapeutics for the treatment of neuropathic pain and epilepsy. The company was founded by Jeffrey A. M. Coull, Yves De Koninck and Martin Gagnon in 2004 and is headquartered in Laval, Canada. | Commercial Services |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Distribution Services |
Gestion Fonds InnovExport Commandité inc
![]() Gestion Fonds InnovExport Commandité inc Investment ManagersFinance Gestion Fonds InnovExport Commandité inc (Fonds Innovexport) is a venture capital firm founded in 2016. The firm is headquartered in Quebec, Canada. | Finance |